Each year, more than five million people in the United States are infected with human papillomavirus-some strains of which can cause genital warts and cancers-during sex. One of the most common causes of sexually transmitted disease, the virus is highly contagious, and so far, nobody has come up with a way to fight it directly. Doctors can remove the warts with chemicals, lasers or other means, but the virus isn’t affected. Now Quebec-based Origenix Technologies is testing a drug the company believes will combat both the warts and the virus by blocking the microbe’s ability to replicate.
The drug is a specially modified DNA molecule that interferes with one of the genes the virus uses to replicate itself once it infects a human cell. Origenix has completed animal testing of a cream containing the drug, says executive vice president Anthony Payne. The company hopes to begin U.S. clinical trials this summer.
Meta has built a massive new language AI—and it’s giving it away for free
Facebook’s parent company is inviting researchers to pore over and pick apart the flaws in its version of GPT-3
The gene-edited pig heart given to a dying patient was infected with a pig virus
The first transplant of a genetically-modified pig heart into a human may have ended prematurely because of a well-known—and avoidable—risk.
Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging
The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.
Yann LeCun has a bold new vision for the future of AI
One of the godfathers of deep learning pulls together old ideas to sketch out a fresh path for AI, but raises as many questions as he answers.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.